Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:DSGN NYSE:PLX NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.22+0.6%$7.46$6.13▼$17.43$644.48M1.461.93 million shs534,075 shsDSGNDesign Therapeutics$10.34+1.6%$12.29$3.33▼$17.25$645.21M1.63516,642 shs398,812 shsPLXProtalix BioTherapeutics$1.98-0.8%$2.12$1.32▼$3.19$159.13M-0.021.08 million shs681,104 shsTLRYTilray Brands$5.14-4.6%$6.18$3.51▼$23.20$598.48M1.884.35 million shs2.47 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-3.31%-1.21%+4.88%+14.75%-35.67%DSGNDesign Therapeutics-2.59%-10.79%-23.53%-1.93%+152.99%PLXProtalix BioTherapeutics-3.16%-6.78%-5.90%-29.51%+26.27%TLRYTilray Brands-2.00%-1.28%-12.66%-26.30%+32.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$8.22+0.6%$7.46$6.13▼$17.43$644.48M1.461.93 million shs534,075 shsDSGNDesign Therapeutics$10.34+1.6%$12.29$3.33▼$17.25$645.21M1.63516,642 shs398,812 shsPLXProtalix BioTherapeutics$1.98-0.8%$2.12$1.32▼$3.19$159.13M-0.021.08 million shs681,104 shsTLRYTilray Brands$5.14-4.6%$6.18$3.51▼$23.20$598.48M1.884.35 million shs2.47 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-3.31%-1.21%+4.88%+14.75%-35.67%DSGNDesign Therapeutics-2.59%-10.79%-23.53%-1.93%+152.99%PLXProtalix BioTherapeutics-3.16%-6.78%-5.90%-29.51%+26.27%TLRYTilray Brands-2.00%-1.28%-12.66%-26.30%+32.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.75Moderate Buy$15.0082.50% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5059.65% UpsidePLXProtalix BioTherapeutics 3.00Buy$12.00507.59% UpsideTLRYTilray Brands 2.25Hold$11.50123.95% UpsideCurrent Analyst Ratings BreakdownLatest PLX, CRMD, DSGN, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026DSGNDesign Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/4/2026DSGNDesign Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $21.004/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026DSGNDesign Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.004/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.004/28/2026CRMDCorMedix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.004/27/2026CRMDCorMedix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$400.05M1.61$1.99 per share4.13$5.14 per share1.60DSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/APLXProtalix BioTherapeutics$76.38M2.08$0.11 per share17.80$0.47 per share4.20TLRYTilray Brands$821.31M0.73$1.35 per share3.80$14.04 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix$163.05M$2.133.8654.79N/A45.25%45.57%24.76%8/6/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.18N/A6.37N/A-21.03%-30.89%-11.74%N/ATLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/27/2026 (Estimated)Latest PLX, CRMD, DSGN, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/A4/1/2026Q3 2026TLRYTilray Brands-$0.14-$0.24-$0.10-$0.24$201.35 million$206.73 million3/9/2026Q4 2025DSGNDesign Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/A3/5/2026Q4 2025CRMDCorMedix$0.86$0.16-$0.70$0.16$127.02 million$128.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedix0.332.972.74DSGNDesign TherapeuticsN/A22.2822.28PLXProtalix BioTherapeuticsN/A1.981.27TLRYTilray Brands0.192.791.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%DSGNDesign Therapeutics56.64%PLXProtalix BioTherapeutics16.53%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix3.50%DSGNDesign Therapeutics17.10%PLXProtalix BioTherapeutics6.50%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3078.45 million75.71 millionOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionablePLXProtalix BioTherapeutics20080.57 million69.00 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionablePLX, CRMD, DSGN, and TLRY HeadlinesRecent News About These CompaniesIs This Why Tilray Brands Inc. (TLRY) is one of the Best Sin Stocks to Buy?29 minutes ago | finance.yahoo.com3 Canadian Marijuana Stocks That Could Help You Make Money3 hours ago | marijuanastocks.comMSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3 at 10:03 AM | finance.yahoo.comSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3 at 7:11 AM | financialpost.comFSweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This SummerJune 3 at 7:00 AM | globenewswire.comTilray Brands, Inc. (TLRY) Stock Slides as Market Rises: Facts to Know Before You TradeJune 2 at 11:40 PM | finance.yahoo.comTilray Brands, Inc. (TLRY) Stock Slides as Market Rises: Facts to Know Before You TradeJune 2 at 7:00 PM | zacks.comTop Cannabis Stocks To Add to Your Watchlist - May 31stJune 1 at 5:02 AM | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Trading Down 2.5% - Should You Sell?May 31 at 5:11 AM | americanbankingnews.comPromising Cannabis Stocks To Consider - May 28thMay 31 at 4:23 AM | americanbankingnews.comCuraleaf Prepares for US Exchange Uplisting: Time to Invest?May 29, 2026 | zacks.comTilray Brands (NASDAQ:TLRY) Stock Price Up 1.8% - Here's WhyMay 28, 2026 | marketbeat.comTop Canadian Marijuana Stocks for Your Watchlist Before June 2026May 28, 2026 | marijuanastocks.comMPremium Craft Cannabis Brand Broken Coast Launches Cherry Ztripez Flower and Pre-Rolls for SummerMay 28, 2026 | finance.yahoo.comPremium Craft Cannabis Brand Broken Coast Launches Cherry Ztripez Flower and Pre-Rolls for SummerMay 28, 2026 | financialpost.comFPremium Craft Cannabis Brand Broken Coast Launches Cherry Ztripez Flower and Pre-Rolls for SummerMay 28, 2026 | globenewswire.comTilray Brands (NASDAQ:TLRY) Trading 1.8% Higher - Here's WhyMay 27, 2026 | marketbeat.comHere's why Tilray Brands stock has crashed: will it rebound soon?May 27, 2026 | invezz.comITilray Brands, Inc.: BrewDog Turns This Summer's Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match MomentsMay 27, 2026 | finanznachrichten.deBrewDog Turns This Summer’s Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match MomentsMay 27, 2026 | finance.yahoo.comBrewDog Turns This Summer's Global Football Tournament into a Nationwide Celebration of Beer, Bars and Big Match MomentsMay 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLX, CRMD, DSGN, and TLRY Company DescriptionsCorMedix NASDAQ:CRMD$8.22 +0.05 (+0.60%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Design Therapeutics NASDAQ:DSGN$10.34 +0.17 (+1.62%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Protalix BioTherapeutics NYSE:PLX$1.98 -0.02 (-0.75%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Tilray Brands NASDAQ:TLRY$5.14 -0.25 (-4.55%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
